Objective: To identify predictors of left ventricular ejection fraction (LVEF) improvement in patients with newly detected cardiomyopathy using wearable cardioverter defibrillators (WCDs).
| INTRODUCTION
A left ventricular ejection fraction (LVEF) <35% is associated with increased risk of sudden cardiac death (SCD) in patients with newly diagnosed symptomatic heart failure. 1, 2 As LVEF improves, the risk for heart failure hospitalization and SCD decreases. 1 Current guidelines recommend implantable cardioverter defibrillator (ICD) placement for primary prevention of SCD in patients with symptomatic heart failure and LVEF <35%. 3 In patients with ischemic cardiomyopathy, the DINAMIT and IRIS studies showed some arrhythmic benefit, but no mortality benefit with immediate ICD implantation. 4, 5 Therefore, current guidelines recommend a waiting period prior to ICD implantation during which patients can still be at risk for SCD. It is during this waiting period that wearable cardioverter defibrillators (WCDs), or "lifevests," are used as a bridge to ICD placement. 6, 7 WCDs have been shown to successfully treat arrhythmic events from ventricular tachycardia (VT) or ventricular fibrillation (VF) in several observational studies including the WEARIT/BIROAD, aggregate U.S. nationwide data from the manufacturer (ZOLL, Pittsburgh, PA), and WEARIT II. [8] [9] [10] However, the VEST trial, which was the first randomized clinical trial looking at ischemic cardiomyopathy patients with reduced LVEF wearing WCDs, did not show any benefit of the WCD reducing arrhythmic deaths (1.6% vs 2.4%, P = .18). 11 Overall, strong clinical data on the effectiveness of WCDs is lacking.
The WEARIT II study also showed that nearly half of the patients with cardiomyopathy had improvement in LVEF, following which an ICD was no longer indicated. 10 Optimal medical therapy using beta-blockers (BB), angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), angiotensin receptor-neprilysin inhibitors (ARNI), aldosterone antagonists, and cardiac resynchronization therapy (CRT) has been shown to improve LVEF and overall survival in patients with moderate to severe left ventricular dysfunction. 12 However, data is limited regarding the clinical variables that predict improvement in LVEF. A sub-study of the MADIT CRT trial showed that systolic blood pressure (SBP) and left bundle branch block (LBBB) predicted improvement in LVEF in patients who received an ICD. 13 Our study aimed to determine the clinical predictors of improvement in LVEF in patients with newly diagnosed cardiomyopathy who were prescribed a WCD. We further looked at the effectiveness of WCDs in preventing arrhythmic events in this patient population.
| METHODS

| Study population
We identified all patients above 18 years of age at Rochester Regional Health (RRH) Hospitals with newly diagnosed cardiomyopathy (LVEF <35%) who received WCDs (product of ZOLL Medical Corporation Inc.) for primary prevention of SCD between November 2013 and November 2015. Technical details of the WCD have been previously described. 7 Patients who did not have follow up within the RRH network were excluded. The institutional review board approved the study, and a waiver of consent was obtained. All patients were expected to receive guideline-directed medical treatment for reduced LVEF, and WCDs were prescribed for primary prevention of SCD.
WCD placement was based on physician discretion and a shared doctor-patient decision making process.
| Data collection and follow up
Clinical variables, ECG, and echocardiographic data for all patients were collected from electronic health records. Patients were followed for a period of 2 years or until their LVEF recovered (>50%), whichever came sooner. Echocardiographic data was used to assess baseline LVEF at the time of WCD placement as well as subsequent LVEF measurements. Improvement in LVEF was defined as LVEF ≥35%, and an increase of ≥10% from their baseline LVEF. Final change in LVEF was determined by the difference between the patient's initial and subsequent LVEF measurements. WCD data that included arrhythmias (VT or VF), shock therapy, and nonshockable rhythms (pulseless electrical activity, asystole) were obtained from the RRH cardiac electrophysiology device management division. The clinical decision for ICD implantation was based on ACC/AHA/HRS guidelines for primary prevention of SCD in patients with cardiomyopathy, or secondary prevention of SCD in patients demonstrating sustained VT, VF, or appropriate WCD shocks. 14 Chi-square or Fischer exact test for dichotomous variables, standard t-test for normal continuous variables, and Kruskal-Wallis for nonparametric variables. A two-sided P < .05 was considered statistically significant. Univariate variables with a P < .1 were then entered into a multivariate logistic regression model, to determine independent predictors of LVEF improvement. All nonnormal continuous data was transformed using statistical functions to normalize the distribution. Results were expressed as odds ratios (with 95% confidence intervals) with respective P values. WCD data on the frequency of arrhythmias represents the percentage of patients who experienced an event, and the type of event.
| Statistical analysis
| RESULTS
Over the 2-year period, 269 patients were identified to have new onset cardiomyopathy with LVEF <35% that were prescribed WCDs.
One hundred seventy-nine patients met the inclusion criteria and had complete data sets to be included in the statistical analysis. Of the 90 patients excluded, 13 were lost to follow up and 77 were limited by either incomplete data or follow up outside the RRH network. Table 1 shows the baseline characteristics of the study population. In 97 patients with ICM, 41.2% (40 patients) showed LVEF improvement over a median duration of 84 days (IQR 45, 120). Of these, 17.5% improved within 40 days, 40% improved in 40-90 days, and 42.5% improved beyond 90 days. Coronary artery revascularization occurred in 87.6%. In 82 patients with NICM, 54.9% (45 patients) showed LVEF improvement over a median duration of 104.5 days (IQR 64.5, 184.5). Of these, 44.4% improved within 90 days, 35.6% improved in 90 days-9 months, and 20% improved beyond 9 months. 
| DISCUSSION
Our study had the following important findings for patients with newly diagnosed cardiomyopathy and LVEF <35% with prescribed WCDs: (a) nearly half experienced improvement in LVEF ≥35%;
(b) baseline LVEF and etiology of cardiomyopathy did not affect LVEF improvement; (c) a greater percentage of patients demonstrated LVEF improvement when the waiting period was extended beyond 90 days;
(d) simple baseline clinical and laboratory data can be used to predict LVEF improvement; and (e) WCD use as a bridge to ICD implantation helps protect against arrhythmic events in high risk patients.
Previous studies have demonstrated reduced LVEF as a predictor of SCD in patients with cardiomyopathy. 1,2 ICD implantation has been shown to reduce the long term risk of SCD in sub studies of the MADIT-II, however data is limited in the short term setting (<90 days). 4, 15, 16 WCDs have therefore been used during this period. Similar to prior studies, we were able to demonstrate close to 50% patients showing LVEF improvement ≥35%. 10, 17, 18 Furthermore, similar to the WEAR-IT II study, we were also able to demonstrate the etiology of cardiomyopathy, ischemic vs nonischemic, not influencing LVEF improvement.
A few studies have tried to identify clinical predictors of LVEF improvement and reverse remodeling, but differ from our study in meth- irrespective of their baseline, and showed female sex, no prior myocardial infarction (MI), NICM, and no digoxin use associated with LVEF improvement. 20 (c) Brenyo et al studied patients from the MADIT-CRT with LVEF <30% and QRS ≥130 ms and showed shorter QRS, higher SBP, low creatinine, and NICM as predictors of left ventricular reverse remodeling. 21 In patients with newly diagnosed cardiomyopathy prescribed a WCD, our study is the first to demonstrate the absence of LBBB, lower BUN, and use of ACEI/ARB as independent predictors of LVEF improvement. Previous studies that associated LBBB and higher BUN with a reduced likelihood of left ventricular (LV) reverse remodeling centered around patients getting ICDs after a waiting period, much later in the disease process. [22] [23] [24] [25] Elevated BUN is often viewed as a prognostic marker that reflects an impaired hemodynamic status proportionate to the reduction in cardiac output. 26 The neuro-hormonal changes that occur in patients with heart failure and cardiomyopathy are reflected more on BUN than creatinine (which closely mimics estimated glomerular filtration rate-eGFR). 27 LBBB on the other hand results in electrical and mechanical dyssynchrony. 28, 29 Findings from the MADIT-CRT have shown LBBB preventing LV reverse remodeling, and absence of LBBB or correction of LBBB using a CRT device correcting this "dyssynchrony" with improvement in LV function. 30, 31 Another sub-study of the MADIT-CRT also showed increasing heart failure events in patients with LBBB, as compared to those with RBBB or nonspecific intraventricular conduction delay. 13 Although a QRS duration ≥150 ms has been shown to negatively predict LVEF improvement, our study lacked statistical power to support this finding. A trend was observed in patients with LVEF improvement having a narrower QRS. With GDMT, we found ACEI/ARB use to be predictive of LVEF improvement, which is consistent with results from prior large scale randomized trials such as the CONSENSUS, CHARM, and SOLVD. [32] [33] [34] Improvement in LVEF ≥35% after a defined waiting period impacts decision making for ICD implantation for primary prevention of SCD. Current ACC/AHA/HRS guidelines recommend a waiting period of 40 days in nonrevascularized post-MI patients, and 90 days in revascularized post MI patients and NICM patients. 35 compliance however is a limiting factor in their use. As noted in our study, one patient died from noncompliance. In current ACC/AHA/ HRS guidelines, the use of a WCD in patients with new onset cardiomyopathy is a class IIb recommendation. We hope that our study offers supportive data for the use of WCDs to treat ventricular arrhythmias during the waiting period prior to ICD implantation.
Our study has the following limitations: (a) given its retrospective nature, we were unable to determine a sequential cause-effect relation- 
| CONCLUSION
In conclusion, in patients with new onset cardiomyopathy, close to half the patients will experience improvement in LVEF. The time to LVEF recovery can extend well beyond 90 days. The absence of LBBB, lower BUN, and use of ACEI/ARB were found to be independent predictors of LVEF improvement. The WCD was effective in treating ventricular arrhythmias during the waiting period prior to ICD implantation.
